Old and new peptide receptor targets in cancer: Future directions

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 567-576

  Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN RECEPTOR; GLUCAGON LIKE PEPTIDE RECEPTOR; INCRETIN RECEPTOR; RECEPTOR; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

AUTORADIOGRAPHY; BINDING SITE; DISEASE ASSOCIATION; GENE OVEREXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; TUMOR CELL;

EID: 84867048380     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_34     Document Type: Review

References (38)

1. Bjenning C, Farrell AP, Holmgren S (1991) Bombesin-like immunoreactivity in skates and the in vitro effect of bombesin on coronary vessels from the longnose skate, Raja rhina. Regul Pept 35:207-219
2. Bunnett G (1994) Gastrin-releasing peptide. Gut peptides: Biochemistry and physiology, New York pp 423-445
3. Cescato R, Maina T, Nock B et al (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49:318-326 (Pubitemid 351225672)
4. Cescato R, Waser B, Fani M et al (2011) Evaluation of 177Lu-DOTA-SST2-antagonist versus 177Lu-DOTA-SST2-agonist binding in human cancers in vitro. J Nucl Med 52:1886-1890
5. Christ E, Wild D, Forrer F et al (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94:4398-4405
6. Clive S, Jodrell D, Webb D (2001) Gastrin-releasing peptide is a potent vasodilator in humans. Clin Pharmacol Ther 69:252-259 (Pubitemid 32382508)
7. Ehses JA, Casilla VR, Doty T et al (2003) Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144:4433-4445 (Pubitemid 37204843)
8. Fleischmann A, Waser B, Reubi JC (2007) Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol 29:421-433 (Pubitemid 47255980)
9. Fleischmann A, Waser B, Reubi JC (2009) High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: Promising candidates for vascular targeting applications. Endocr Relat Cancer 16:623-633
10. Ginj M, Zhang H, Waser B et al (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103:16436-16441 (Pubitemid 44715214)
11. Gugger M, Reubi JC (1999) GRP receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155:2067-2076
12. Heuser M, Schlott T, Schally AV et al (2005) Expression of gastrin releasing Peptide receptor in renal cell carcinomas: A potential function for the regulation of neoangiogenesis and microvascular perfusion. J Urol 173:2154-2159 (Pubitemid 40675272)
13. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
14. Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127-136
15. Irwin N, Flatt PR (2009) Therapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 23:499-512
16. Jensen JA, Carroll RE, Benya RV (2001) The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22:689-699 (Pubitemid 32322728)
17. Kim JS, McKinnis VS, White SR (1997) Migration of guinea pig airway epithelial cells in response to bombesin analogues. Am J Respir Cell Mol Biol 16:259-266 (Pubitemid 127497448)
18. Kim SJ, Nian C, Widenmaier S et al (2008) Glucose-dependent insulinotropic polypeptidemediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 28:1644-1656
19. Korner M, Stockli M, Waser B et al (2007) GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J Nucl Med 48:736-743 (Pubitemid 47604973)
20. Levine L, Licci JA 3rd, Townsend CM Jr et al (2003a) Expression of gastrin-releasing peptide receptors in endometrial cancer. J Am Coll Surg 196:898-904 (Pubitemid 36676551)
21. Levine L, Lucci JA 3rd, Pazdrak B et al (2003b) Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 63:3495-3502 (Pubitemid 36793027)
22. Luu TN, Chester AH, O'Neil GS et al (1993) Different responses of the human gastroepiploic and internal mammary arteries to vasoactive peptides. Am J Physiol 264:H583-H587 (Pubitemid 23081136)
23. Maecke HR, Reubi JC (2011) Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 52:841-844
24. Mansi R, Wang X, Forrer F et al (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7, 10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with singlephoton emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240-5249
25. Mansi R, Wang X, Forrer F et al (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97-107
26. Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res 59:1152-1159 (Pubitemid 29135980)
27. Oberg KE, Reubi JC, Kwekkeboom DJ et al (2010) Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139:742-753 753 e741
28. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427 (Pubitemid 37056239)
29. Reubi JC (2007) Targeting CCK receptors in human cancers. Curr Top Med Chem 7:1239-1242 (Pubitemid 47040510)
30. Reubi JC, Fleischmann A, Waser B et al (2011) Concomitant vascular GRP-receptor and VEGFreceptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature. Peptides 32:1457-1462
31. Reubi JC, Macke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46:67S-75S (Pubitemid 47619021)
32. Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49: 1735-1738
33. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 30:781-793 (Pubitemid 36612963)
34. Waser B, Beetschen K, Pellegata NS et al (2011) Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: Relevance for incretin-based diabetes therapy. Neuroendocrinology 94:291-301
35. Wild D, Caplin M, Christ E et al (2011a) Glucagon-like peptide-1 vs. somatostatin receptor targeting in malignant insulinomas. J Nucl Med 52:1073-1078
36. Wild D, Fani M, Behe M et al (2011b) First clinical evidence that imaging with somatostatin receptor antagonists is clinically feasible. J Nucl Med 52:1412-1417
37. Wild D, Mäcke H, Christ E et al (2008) Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 359:766-768
38. Yule KA, White SR (1999) Migration of 3T3 and lung fibroblasts in response to calcitonin generelated peptide and bombesin. Exp Lung Res 25:261-273 (Pubitemid 29210663)